IL287073A - Methods and materials for gender-dependent treatment of cardiovascular dysfunction - Google Patents

Methods and materials for gender-dependent treatment of cardiovascular dysfunction

Info

Publication number
IL287073A
IL287073A IL287073A IL28707321A IL287073A IL 287073 A IL287073 A IL 287073A IL 287073 A IL287073 A IL 287073A IL 28707321 A IL28707321 A IL 28707321A IL 287073 A IL287073 A IL 287073A
Authority
IL
Israel
Prior art keywords
gender
materials
methods
cardiovascular dysfunction
dependent treatment
Prior art date
Application number
IL287073A
Other languages
English (en)
Hebrew (he)
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of IL287073A publication Critical patent/IL287073A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL287073A 2019-04-10 2021-10-07 Methods and materials for gender-dependent treatment of cardiovascular dysfunction IL287073A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832139P 2019-04-10 2019-04-10
PCT/US2020/027777 WO2020210707A1 (en) 2019-04-10 2020-04-10 Methods and materials for gender-dependent treatment of cardiovascular dysfunction

Publications (1)

Publication Number Publication Date
IL287073A true IL287073A (en) 2021-12-01

Family

ID=72752121

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287073A IL287073A (en) 2019-04-10 2021-10-07 Methods and materials for gender-dependent treatment of cardiovascular dysfunction

Country Status (11)

Country Link
US (1) US12465605B2 (https=)
EP (1) EP3952992A4 (https=)
JP (2) JP2022526621A (https=)
KR (1) KR20210150495A (https=)
CN (1) CN114144229A (https=)
AU (2) AU2020273183A1 (https=)
CA (1) CA3136550A1 (https=)
IL (1) IL287073A (https=)
MX (2) MX2021012409A (https=)
SG (1) SG11202110533RA (https=)
WO (1) WO2020210707A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117357506A (zh) * 2023-09-11 2024-01-09 重庆医科大学国际体外诊断研究院 丹酚酸a在治疗钙化性主动脉瓣膜疾病中的用途
CN117969836B (zh) * 2024-03-29 2024-06-04 北京市心肺血管疾病研究所 基于血浆炎症蛋白构建主动脉瓣钙化狭窄诊断模型及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR22934E (fr) 1919-07-19 1921-09-06 Albert Jean Baptiste Hanotelle Sifflet électro-automoteur perfectionné pour répétition des signaux sur la locomotive
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
PL339836A1 (en) 1998-02-19 2001-01-02 Eisai Co Ltd Phtalazine compounds and therapeutic agents suitable to treat erection disorders
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CA2406947A1 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
EP1366049B1 (en) 2000-06-23 2006-06-21 Lilly Icos LLC Pirazino¬1'2':1,6|pyrido¬3,4-b|indole derivatives
ES2269408T3 (es) 2000-06-23 2007-04-01 Lilly Icos Llc Inhibidores de fosfodiesterasa especifica de gmp ciclico.
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US7091207B2 (en) 2002-05-22 2006-08-15 Virginia Commonwealth University Method of treating myocardial infarction with PDE-5 inhibitors
WO2004037183A2 (en) 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
GB0318094D0 (en) 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
WO2007050585A2 (en) 2005-10-24 2007-05-03 The Johns Hopkins University Use of a nitric oxide synthase modulator for the treatment of cardiac indications
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
GB201114901D0 (en) 2011-08-26 2011-10-12 King S College London Vascular treatments
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CN107580495A (zh) 2015-05-06 2018-01-12 拜耳制药股份公司 单独和与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于治疗伴随系统性硬化症(SSc)的指溃疡(DU)的用途
JP7057365B2 (ja) 2016-09-30 2022-04-19 ゼナメッド コーポレーション ミドドリンの組成物およびその使用方法
EP4620525A3 (en) 2016-12-14 2025-12-03 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Also Published As

Publication number Publication date
WO2020210707A1 (en) 2020-10-15
EP3952992A1 (en) 2022-02-16
CA3136550A1 (en) 2020-10-15
MX2021012409A (es) 2021-11-12
CN114144229A (zh) 2022-03-04
US12465605B2 (en) 2025-11-11
JP2025172729A (ja) 2025-11-26
SG11202110533RA (en) 2021-10-28
AU2025256169A1 (en) 2025-11-13
KR20210150495A (ko) 2021-12-10
EP3952992A4 (en) 2023-04-19
JP2022526621A (ja) 2022-05-25
US20220211702A1 (en) 2022-07-07
MX2024010759A (es) 2024-09-10
AU2020273183A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
IL290677A (en) Brd9 bifunctional degraders and their methods of use
DK4065585T3 (da) Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder
IL271025A (en) Multibiotic agents and methods of using the same
IL272470A (en) Methods and materials for assessing and treating cancer
IL289423A (en) Compounds and methods for treating neurological and cardiovascular conditions
IL291687A (en) Methods for treating myelofibrosis and related conditions
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK4206216T3 (da) Adeno-associerede virusvarianter og fremgangsmåder til brug deraf
IL282441A (en) Conjugated chemical inducers of degradation and methods of use
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL287039A (en) Cd19 antibodies and methods of using the same
IL272321A (en) Methods and compositions for treatment of amyloid deposition diseases
IL283782A (en) Anellosomes and methods of use
EP3603636A4 (en) COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS
IL282424A (en) Alk2 antibodies and methods of use thereof
IL281008A (en) Anti-CD33 antibodies and methods of using them
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
IL286437A (en) Materials and methods for enhanced treatment and prevention of biofilms
EP3630046C0 (en) ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE THEREOF
IL288086A (en) Methods and materials for treating cancer
IL271395A (en) Treatment of sexual dysfunction and improvement in sexual quality of life
IL283662A (en) Monomethyl fumarate-carrier conjugates and methods of their use